This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
by Zacks Equity Research
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
ALNYNegative Net Change NVAXNegative Net Change PNo Net Change PCVXPositive Net Change ATHANegative Net Change
biotechnology biotechs medical pharmaceuticals
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
by Zacks Equity Research
BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
BIIBPositive Net Change ILMNPositive Net Change IONSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
by Zacks Equity Research
DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.
DYNNegative Net Change EXELPositive Net Change SRPTPositive Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
by Zacks Equity Research
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
BIIBPositive Net Change EXELPositive Net Change KRYSPositive Net Change DNLIPositive Net Change
biotechnology biotechs pharmaceuticals
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
by Zacks Equity Research
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
ILMNPositive Net Change KRYSPositive Net Change FULCPositive Net Change RXRXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
by Zacks Equity Research
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
GSKPositive Net Change PFEPositive Net Change MRKNegative Net Change PCVXPositive Net Change
biotechs medical pharmaceuticals vaccines
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
by Zacks Equity Research
MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
RHHBYNegative Net Change PFEPositive Net Change MRKNegative Net Change LLYPositive Net Change
pharmaceuticals
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.
NVOPositive Net Change LLYPositive Net Change ABBVNegative Net Change GMABPositive Net Change
pharmaceuticals
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
by Zacks Equity Research
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
ILMNPositive Net Change NBIXPositive Net Change XENEPositive Net Change PRAXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Investment Ideas feature highlights: Meta Platforms, Lockheed Martin and Eli Lilly
by Zacks Equity Research
Meta Platforms, Lockheed Martin and Eli Lilly are part of the Zacks Investment Ideas article.
LMTNegative Net Change LLYPositive Net Change METAPositive Net Change
aerospace internet-content pharmaceuticals
Top Medical Stocks to Hedge Against the September Effect
by Shaun Pruitt
Often sought out for defensive protection amid heightened market volatility, medical stocks may be of interest to investors in September which has historically been the most challenging month for stocks.
LLYPositive Net Change DVAPositive Net Change HCAPositive Net Change
earnings hospitals investing large-cap medical medical-devices pharmaceuticals stock-performance value-stocks volatility
Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
by Zacks Equity Research
AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.
ILMNPositive Net Change KRYSPositive Net Change AMRXPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Big Winners from the Q2 Earnings Season: LLY, LMT, META
by Derek Lewis
The 2024 Q2 earnings season is slowly grinding to a halt, with the majority of S&P 500 companies already delivering quarterly results. And during the period, these three companies stole the spotlight.
LMTNegative Net Change LLYPositive Net Change METAPositive Net Change
aerospace pharmaceuticals tech-stocks
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
by Kinjel Shah
BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.
BIIBPositive Net Change LLYPositive Net Change SAGENegative Net Change
biotechs pharmaceuticals
Viking Surges 342% in the Past Year: How Should You Play the Stock?
by Sundeep Ganoria
VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change MDGLPositive Net Change
biotechs medical pharmaceuticals
Terns Surges 29.6% in Three Months: Will the Momentum Continue?
by Zacks Equity Research
TERN has outperformed the industry in the past three months on encouraging pipeline progress of its candidates. Positive data on obesity candidates should boost the stock further.
NVSPositive Net Change EXELPositive Net Change KRYSPositive Net Change TERNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.
SNYNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study
by Zacks Equity Research
BAYRY's late-stage FINEARTS-HF study on finerenone show statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure.
LLYPositive Net Change BAYRYNegative Net Change EXELPositive Net Change
medical pharmaceuticals
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
by Zacks Equity Research
Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
SNYNegative Net Change RHHBYNegative Net Change LLYPositive Net Change ARCTNegative Net Change
pharmaceuticals
Bayer Initiates Late-Stage Study on Investigational NSCLC Drug
by Zacks Equity Research
BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.
LLYPositive Net Change BAYRYNegative Net Change EXELPositive Net Change
medical pharmaceuticals
Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
ILMNPositive Net Change KRYSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
JNJNegative Net Change ARGXNegative Net Change FULCPositive Net Change BVSPositive Net Change
biotechs medical pharmaceuticals
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
by Zacks Equity Research
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
AZNNegative Net Change MRKNegative Net Change FULCPositive Net Change BVSPositive Net Change
biotechs medical pharmaceuticals
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
by Kinjel Shah
LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
RHHBYNegative Net Change JNJNegative Net Change PFEPositive Net Change MRKNegative Net Change LLYPositive Net Change
pharmaceuticals
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
by Zacks Equity Research
Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.
BMYNegative Net Change NBIXPositive Net Change ABBVNegative Net Change FULCPositive Net Change
medical pharmaceuticals